Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Future directions in AML: targeted therapies, antibody-radiation conjugates & new combinations

Amir Fathi • 14 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia Antibodies Lintuzumab-Ac225 Magrolimab

Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the future of acute myeloid leukemia (AML) treatment in a time when numerous novel agents are showing promise in early phase trials. Dr Fathi comments that, while several therapeutics with unique mechanisms of action appear propitious, mature data is needed before conclusions can be drawn. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Amir Fathi

1:17
Venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with AML
Amir Fathi • 21 Nov 2023
2:04
Hot topics in the AML space: menin inhibitors
Amir Fathi • 21 Nov 2023
1:44
Improving maintenance therapy in AML: exploring the role of IDH inhibitors
Amir Fathi • 21 Nov 2023
1:12
Managing adverse risk AML: clinical considerations & future outlooks
Amir Fathi • 21 Nov 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals